The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism

Browse trials for

• Hypogonadism 345

Keywords

• endothelial dysfunction
• bone mineral metabolism
• testosteron replacement treatment

Hypogonadism

345 studies on the registry are indexed under Hypogonadism; 43 are open to participants now.

This study's enrollment of 49 is below the median of 56 across 260 interventional studies indexed under Hypogonadism.

Lead sponsor

Gulhane School of Medicine is the lead sponsor of 66 studies on the registry; 4 are open to participants now.

Study arms

• Other
  testosterone

  testosterone 250 mg injection per 3-4 weeks for 6 months

  Drug: Testosterone

Interventions

• DrugTestosterone

  Testosterone 250 mg injection per 3-4 weeks for 6 months

  Also known as: sustanon 250 mg

Primary outcomes

1. the effect of testosteron replacement treatment on the Fibroblast Growth Factor-23.

   Plasma FGF-23 levels were determined by ELISA, (Human Intact FGF-23 ELISA Kit, Inc., San Clement, CA, USA).

   Time frame: 6 months

2. the effect of testosteron replacement treatment on the asymmetric dimethylarginine.

   Plasma ADMA levels were determined by ELISA (Immunodiagnostic, Bernheim, Germany)

   Time frame: 6 months

3. the effect of testosteron replacement treatment on the vitamin D levels.

   Plasma 25-OH vitamin D3 levels were measured by Immuchrom kits (Hessen, Germany) using isocratic HPLC method with UV detector in Prominence HPLC system.

   Time frame: 6 months.